46. Malignant rheumatoid arthritis Clinical trials / Disease details

Clinical trials : 4,325 / Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224

5 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05267431 (ClinicalTrials.gov)	June 2022	14/2/2022	Outcomes of Biological Therapy on Rheumatoid Arthritis	Outcomes of Different Biological Therapy on Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Biological Drug	Sohag University	NULL	Not yet recruiting	18 Years	N/A	All	200		Egypt
2	NCT04470453 (ClinicalTrials.gov)	October 8, 2020	9/7/2020	Association Between Methotrexate Erythrocyte Polyglutamate Concentration and Biological Drug Concentration and Clinical Response in Rheumatoid Arthritis Patients Treated With Subcutaneous Injectable Methotrexate and a First Biological Drug	Association Between Methotrexate Erythrocyte Polyglutamate Concentration and Biological Drug Concentration and Clinical Response in Rheumatoid Arthritis Patients Treated With Subcutaneous Injectable Methotrexate and a First Biological Drug	Rheumatoid Arthritis	Biological: Blood sample;Diagnostic Test: CRQ	Centre Hospitalier Universitaire de Saint Etienne	NULL	Recruiting	18 Years	N/A	All	60	Phase 4	France
3	EUCTR2019-003700-12-FR (EUCTR)	13/03/2020	04/06/2020	Association between metabolits of methotrexate and clinical response in rheumatoid arthritis patients	Association between methotrexate erythrocyte polyglutamate concentration and biological drug concentration and clinical response in rheumatoid arthritis patients treated with subcutaneous injectable methotrexate and a first biological drug	rheumatoid arthritis MedDRA version: 21.0;Level: LLT;Classification code 10042952;Term: Systemic rheumatoid arthritis;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: Methotrexate Product Code: MTX Other descriptive name: METHOTREXATE DISODIUM Product Code: bDMARD INN or Proposed INN: INFLIXIMAB INN or Proposed INN: ETANERCEPT INN or Proposed INN: ADALIMUMAB INN or Proposed INN: CERTOLIZUMAB PEGOL INN or Proposed INN: GOLIMUMAB	CHU Saint-Etienne	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	60	Phase 4	France
4	EUCTR2009-012041-35-FR (EUCTR)	27/11/2009	16/10/2009	A phase II, randomized, partially double blind, controlled study to evaluate the immunogenicity, safety, and clinical efficacy of three doses of Neovacs’ TNF-Kinoid in adult patients with rheumatoid arthritis (RA) who have relapsed despite use of an anti-TNFa biological drug, due to anti-drug antibodies	A phase II, randomized, partially double blind, controlled study to evaluate the immunogenicity, safety, and clinical efficacy of three doses of Neovacs’ TNF-Kinoid in adult patients with rheumatoid arthritis (RA) who have relapsed despite use of an anti-TNFa biological drug, due to anti-drug antibodies	Rheumatoid arthritis MedDRA version: 12.0;Level: PT;Classification code 10039073;Term: Rheumatoid arthritis	Product Name: TNF-Kinoid Product Code: TNF-K	Neovacs SA	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	48	Phase 2	Bulgaria;France
5	NCT03496831 (ClinicalTrials.gov)	January 1, 2006	5/4/2018	Predicting Hospitalized Infection in Patients With Chronic Inflammatory Arthritis Treated With Biological Drugs	Development of a Prediction Model for the Risk of Hospitalized Infection in Patients With Chronic Inflammatory Arthritis Treated With Biological Drugs	Rheumatoid Arthritis;Spondyloarthritis;Psoriatic Arthritis	Drug: Biologic Agents	Simon Krabbe	University of Aarhus;Zealand University Hospital;University of Southern Denmark	Completed	18 Years	N/A	All	7500		NULL